Gyre Therapeutics (GYRE) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Gyre Therapeutics (GYRE) over the last 12 years, with Q3 2025 value amounting to $6.9 million.
- Gyre Therapeutics' Accumulated Depreciation & Amortization rose 3026.49% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 3026.49%. This contributed to the annual value of $5.6 million for FY2024, which is 3127.78% up from last year.
- Per Gyre Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $6.9 million for Q3 2025, which was up 3026.49% from $6.4 million recorded in Q2 2025.
- Over the past 5 years, Gyre Therapeutics' Accumulated Depreciation & Amortization peaked at $6.9 million during Q3 2025, and registered a low of $4.0 million during Q4 2022.
- Moreover, its 4-year median value for Accumulated Depreciation & Amortization was $5.3 million (2024), whereas its average is $5.3 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 667.83% in 2023, then skyrocketed by 3374.27% in 2025.
- Gyre Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $4.0 million in 2022, then increased by 6.68% to $4.3 million in 2023, then surged by 31.28% to $5.6 million in 2024, then grew by 23.84% to $6.9 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $6.9 million for Q3 2025, versus $6.4 million for Q2 2025 and $6.1 million for Q1 2025.